Monoclonal antibodies that target mediators of the inflammatory response
Anti-tumor necrosis factor agents
- Infliximab (Remicade)
- Adalimumab (Humira)
- Golimumab (Simponi)
- Vedolizumab (Entyvio)
- gut-selective and is not associated with an increased risk of serious infection or malignancy
- symptomatic improvement within six weeks
Interleukin inhibitor
- Ustekinumab (Stelara)
- Mirikizumab
Janus kinase inhibitors (NOT an Monoclonal antibody)
- Tofacitinib (Xeljanz)
- Upadacitinib (Rinvoq)
Sphingosine-1-phosphate (S1P) receptor modulators
- Ozanimod
- Etrasimod
Side effects: infection, malignancy, lymphomas, immunogenicity
Exclude TB prior to using